TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04164238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: 5-fu injection
Study: NCT00957359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
Study: NCT04120935

Intervention type: OTHER
Intervention: Observation
Description: Prospective Observation of standard clinical practice.
Study: NCT01070680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Precedex
Description: mkg/ml,continuous infusion at rate 0.7 µg/kg/h
Study: NCT01308138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: remote ischemic preconditioning
Study: NCT02930226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Freeze Dried Plasma (FDP)
Description: Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Description: Controlled FFP in cohort 3 only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Description: Controlled FFP in cohort 3 only
Study: NCT01234051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin
Description: 1. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days.
Study: NCT01331486

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hawthorn
Description: Hawthorn standardized extract liquid capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hawthorn
Description: Hawthorn standardized extract liquid capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hawthorn
Description: Hawthorn standardized extract liquid capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Matched placebo liquid capsule
Study: NCT03210922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miami cervical collar
Description: Collar group is put on the Miami cervical collar.
Study: NCT01070680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chlorid 0,9%
Description: continuous intravenous infusion
Study: NCT02061657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo( for misoprostol)
Description: Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
Study: NCT02170714

Intervention type: OTHER
Intervention: Clinical and laboratory assessment
Description: Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
Study: NCT05232617

Intervention type: OTHER
Intervention: Rheumatological rehabilitation training
Description: Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
Study: NCT00384631

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: subconjunctival normal saline
Description: 0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
Study: NCT04519424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL324
Description: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride)
Study: NCT03163732

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood and tumor samples
Description: Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood and tumor samples
Description: Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
Study: NCT02774239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human normal immunoglobulin G (IgG)
Description: Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner.
Study: NCT00646516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Study: NCT01879267

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise training
Description: 6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise training
Description: 6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
Study: NCT00695019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha lozenges
Description: 500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha lozenges
Description: 500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo lozenges
Description: 200 mg matching placebo lozenges
Study: NCT01031082

Intervention type: PROCEDURE
Intervention: Middle ear fluid, nasopharyngeal aspirate and urine sample.
Description: Middle ear fluid, nasopharyngeal aspirate and urine sample collection.

Intervention type: PROCEDURE
Intervention: Middle ear fluid, nasopharyngeal aspirate and urine sample.
Description: Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
Study: NCT03858322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Study: NCT01542281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and dietary supplements
Description: Whey protein and dietary supplements in addition to pre-hab exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prehab exercise
Description: minimum 4 weeks and maximum 8 weeks; 3 times a week
Study: NCT02991079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)
Study: NCT03100877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03652896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
Study: NCT00623675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineralox C
Description: Mineralox C 2 capsules three times a day.
Study: NCT00314145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE
Description: 0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX®
Description: 0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
Study: NCT03100877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV
Study: NCT01794468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal blood flow measurements
Description: Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
Study: NCT04140110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering
Description: The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
Study: NCT01997658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
Study: NCT01641536

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HB-110
Description: Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HB-110
Description: Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HB-110
Description: Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
Study: NCT01612195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Description: All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
Study: NCT02713672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjustment according to genotype
Description: Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
Study: NCT06048224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS628+MTX
Description: Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actemra +MTX
Description: Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
Study: NCT00922584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib (Nexavar)
Description: oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
Study: NCT00888836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery: Gastric bypass
Description: Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery: Bilio-pancreatic diversion
Description: Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-diabetic drugs and behavioral suggestions
Description: Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
Study: NCT01767337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLUGEN 101.2 device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLUGEN 101.2 device
Study: NCT03100877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01767337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLUGEN 101.2 device
Study: NCT01563783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global Fibroid Ablation (GFA)
Description: GFA is being used for the treatment of symptomatic uterine fibroids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global Fibroid Ablation (GFA)
Description: GFA is being used for the treatment of symptomatic uterine fibroids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal or Laparoscopic Myomectomy
Description: Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Artery Embolization (UAE)
Description: UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
Study: NCT00216372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (microparticle formulation)
Description: A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intra-muscular injection on day 0.
Study: NCT01555593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioline Exp'air by Medi-soft - Sorinnes (B)
Description: FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
Study: NCT03617887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
Study: NCT01867255

Intervention type: DRUG
Group type: OTHER
Intervention: venlafaxine ER (extended-release) 75 mg
Description: A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.